ChainUp, a global leader in digital asset technology, has earned a spot on the inaugural Singapore's Top Fintech Companies 2026 list. This prestigious ranking is a first-time collaboration between Tech in Asia, the region's top tech media outlet, and Statista, a world-renowned data provider. Together, they analyzed over 500 firms to identify the innovators truly […]
ChainUp, a global leader in digital asset technology, has earned a spot on the inaugural Singapore's Top Fintech Companies 2026 list. This prestigious ranking is a first-time collaboration between Tech in Asia, the region's top tech media outlet, and Statista, a world-renowned data provider. Together, they analyzed over 500 firms to identify the innovators truly
(SWX:SANN), Commercial launch in Switzerland anticipated in H2 2026 Pratteln, Switzerland, January 15, 2026 – Santhera Pharmaceuticals (SIX: SANN) announces that the Swiss Agency for Therapeutic Products (Swissmedic), has approved AGAMREE(R) (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) in patients four years of age and older. Dario Eklund, Chief Executive Officer of Santhera,
(SWX:ASCN), Ad hoc announcement pursuant to Art. 53 LRBaar (Switzerland), 15 January 2026 Based on preliminary unaudited figures, Ascom reports for fiscal year 2025 net revenue of CHF 292.1 million, which is an increase of around 3.8% at constant currencies, and an EBITDA margin of around 11.5% to 12.0%. Ascom generated net revenue of CHF
Santhera Receives Swissmedic Approval of AGAMREE(R) (Vamorolone) for the Treatment of Duchenne Muscular Dystrophy GlobeNewswire January 15, 2026 Commercial launch in Switzerland anticipated in H2 2026 Pratteln, Switzerland, January 15, 2026 – Santhera Pharmaceuticals (SIX: SANN) announces that the Swiss Agency for Therapeutic Products (Swissmedic), has approved AGAMREE(R) (vamorolone) for the treatment of Duchenne muscular
Ascom preliminary results 2025 GlobeNewswire January 15, 2026 Ad hoc announcement pursuant to Art. 53 LRBaar (Switzerland), 15 January 2026 Based on preliminary unaudited figures, Ascom reports for fiscal year 2025 net revenue of CHF 292.1 million, which is an increase of around 3.8% at constant currencies, and an EBITDA margin of around 11.5% to
Stablepharma and AFT Pharmaceuticals (NZX: AFT; ASX: AFP) partner to address multi-billion dollar anti-infective and oncology therapeutics market GlobeNewswire January 15, 2026 LONDON, Jan. 15, 2026 (GLOBE NEWSWIRE) — Stablepharma Limited, specialists in thermostable formulations, today announced a development and option-to-license agreement with AFT Pharmaceuticals to develop a portfolio of fridge-free sterile injectable medicines, initially
Press Release: Myqorzo and Redemplo approved in China GlobeNewswire January 15, 2026 Myqorzo and Redemplo approved in China Approval of Myqorzo for obstructive hypertrophic cardiomyopathy and Redemplo for familial chylomicronemia syndrome Underscores Sanofi's long-term commitment to China, reinforcing the ambition to provide transformative medicines to patients in disease areas with large unmet medical needs Paris,
(Strategic Expansion Positions YI TING as Resilient Supply Partner, Cutting Lead Times By Up to 30% for Sustainable Filtration) Trusted by world-renowned specialty coffee equipment innovators and Tier-1 roasters, YI TING Non-Woven, a leading Taiwanese manufacturer of engineered nonwoven materials, today announced a major capacity doubling to scale support for its rapidly growing client base
A news report from Haikou Municipal Bureau of Tourism, Culture, Radio, Television and Sports: Recently, the “Haikou on Stage, Dancing with the World” International Performing Arts Capital Promotion Conference was successfully held in Haikou. Centered on the theme “Culture Empowering Cities, Art Illuminating the Future,” the event combined immersive audiovisual experiences with in-depth industry dialogue,